Results 141 to 150 of about 13,126 (223)

Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Khan SM, Abboud I, Elhusseiny AM, Elhusseiny AM.   +3 more
europepmc   +1 more source

Effectiveness of Maternal Respiratory Syncytial Virus Vaccination in Conferring Infant Immunity: Review and Future Perspectives. [PDF]

Vaccines (Basel)
Kaneko M, Muraoka J.
europepmc   +1 more source

A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025. [PDF]

Transl Clin Pharmacol
Koo S, Kim CY, Lim JH, Lee E, Kim IY, Shin YG, Moon H.   +6 more
europepmc   +1 more source

AKI After Hepatic Histotripsy. [PDF]

Kidney Int Rep
Bhutta S, Wanchoo R, Sakhiya V, Gholami S, Devoe C, Jhaveri KD.   +5 more
europepmc   +1 more source

Safety profile and potential clinical risks of xanomeline and trospium chloride: A real-world pharmacovigilance study using FAERS. [PDF]

Neurotherapeutics
Bao Z, Liu Y, Liu Y.
europepmc   +1 more source

Physician Rewards for Postmarketing Surveillance (Seeding Studies) in the US

, 1995
La Puma, John
core   +1 more source

A practical framework to approach the development and evaluation of patient registries for rare diseases. [PDF]

Orphanet J Rare Dis
Vaishnaw MS, Richesson R.
europepmc   +1 more source

Evolving Real-World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan-An Analysis of the 6-Year Trend. [PDF]

Clin Pharmacol Ther
Okami S, Shimotsumagari K, Sadatsuki Y.
europepmc   +1 more source

CSM Proposals for Improved Postmarketing Surveillance

, 1978

core  

Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments. [PDF]

Clin Pharmacol Ther
Kitagaki H, Takeda K, Murai K, Maeda H.
europepmc   +1 more source